Main Uses and Therapeutic Action

Вис-Нол is a gastro-protective medication primarily used to manage inflammatory and ulcerative conditions of the upper gastrointestinal tract. The active substance, bismuth subcitrate, works by forming a protective barrier over damaged mucosal tissues, such as ulcers and erosions. This coating helps shield the affected areas from the irritating effects of gastric acid and digestive enzymes, allowing the underlying tissue to heal.

Targeting Helicobacter pylori

One of the primary applications of Вис-Нол is in the eradication of Helicobacter pylori (H. pylori). This bacterium is a leading cause of chronic gastritis and peptic ulcers. The medication exhibits antimicrobial activity against these bacteria, and when used as part of a comprehensive treatment regimen, it helps reduce the likelihood of ulcer recurrence by addressing the underlying infection.

Specific Conditions Treated

The medication is typically indicated for the following conditions:

• Peptic Ulcer Disease: This includes both gastric (stomach) and duodenal ulcers, particularly during the acute phase of the disease.
• Chronic Gastritis and Gastroduodenitis: It is used during exacerbations of chronic inflammation in the stomach and the beginning of the small intestine.
• Irritable Bowel Syndrome (IBS): It may be used to manage symptoms when the syndrome is accompanied by diarrhea and functional digestive disturbances.
• Functional Dyspepsia: It helps alleviate symptoms associated with non-ulcer dyspepsia, where organic causes for digestive discomfort are not identified.

Therapeutic Benefits

Beyond forming a physical barrier, Вис-Нол stimulates the body's natural protective mechanisms. It promotes the production of prostaglandins and stimulates the secretion of bicarbonate and mucus. These actions enhance the mucosal-bicarbonate barrier, improving the stomach's resistance to internal and external chemical irritants. Additionally, the medication helps reduce the activity of pepsin, an enzyme that can further damage weakened gastric tissues.

Official Eligibility and Contraindications

The eligibility profile for Вис-Нол (Bismuth Subcitrate) is strictly defined by regulatory authorities, outlining the populations permitted, restricted, or prohibited from using the medicine. Use is primarily established and allowed for adult patients who do not present any specific contraindications.

Category	Regulatory Status
Absolute Contraindication	Patients with known severe renal impairment. Individuals with documented hypersensitivity to Bismuth Subcitrate or any excipient.
Pediatric Eligibility	Not Recommended for children and adolescents under 18 years of age. Safety and effectiveness have not been established in this age group.
Reproductive Status	Pregnancy: Use is not recommended or contraindicated (when part of H. pylori quadruple therapy). Lactation: Use should be avoided or is not recommended.
Use Restriction	Not intended for prolonged use (typically exceeding 8 weeks) in any population due to the risk of systemic bismuth accumulation.

These restrictions ensure the medicine is reserved for the population where its profile is officially deemed acceptable. The most critical constraint is the prohibition in severe renal impairment, where elimination of absorbed bismuth is compromised.

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Вис-Нол (Bismuth Subcitrate) based on authoritative government regulatory documents.

Pharmacokinetic and Absorption Constraints

The most significant interactions involve medicines and products that modify gastric acidity or contain minerals, impacting Bismuth Subcitrate absorption or efficacy.

Product Class/Substance	Official Interaction Description	Resulting Constraint/Note
Gastric Acid-Reducing Agents (e.g., Proton Pump Inhibitors like Omeprazole and H2 -antagonists)	Co-administration increases the systemic absorption of bismuth.	Increased systemic exposure is officially noted.
Antacids and Mineral Supplements (e.g., iron, zinc, calcium)	Efficacy may be reduced due to chelation (binding) of the active ingredient.	Requires mandatory timing separation of at least 30 minutes to 2 hours from Bismuth Subcitrate administration.
Dairy Products (e.g., milk)	Reduced efficacy/absorption due to chelation.	Administration around dosing is officially restricted.

Population-Specific Interaction Relevance

Official labeling indicates that patients with severe renal impairment are at a higher risk of bismuth accumulation from systemically absorbed drug. Therefore, any interaction that increases systemic absorption is of heightened relevance in this population.

No contraindicated combinations are solely attributed to Bismuth Subcitrate as a single component preparation.

The mechanism of action of Вис-Нол, which contains bismuth tripotassium dicitrate, is primarily localized to the gastrointestinal mucosa. Upon ingestion, the compound interacts with the acidic environment of the stomach, leading to the formation of an insoluble precipitate, bismuth oxychloride, and bismuth citrate. This colloidal bismuth complex selectively binds to the glycoprotein-rich necrotic base of mucosal defects, such as erosions and ulcers. This interaction establishes a protective layer or physical barrier over the compromised tissue, shielding it from the digestive action of pepsin and hydrochloric acid.

*Separately, the bismuth compound demonstrates direct antimicrobial activity against Helicobacter pylori through a mechanism involving the non-specific binding to the bacterial cell wall and inhibition of key enzymes, including urease and catalase. Furthermore, it stimulates the local biosynthesis of prostaglandin E2 in the gastric mucosa, which contributes to increased bicarbonate secretion and enhanced mucus production**. The accumulation of the bismuth complex in the submucosa modulates local physiological conditions by altering the mucosal defense factors.

How to Use Вис-Нол (Bismuth Subcitrate): Administration Guidelines

Administration of Вис-Нол follows specific protocols regarding the route, dosing schedule, and timing considerations for use.

Routes and Dosage

Feature	Instruction
Route of Administration	The drug is taken orally.
Dosage Form	Hard gelatin capsules or tablets, typically 120 mg Bismuth Subcitrate equivalent.

---

Standard Dosing and Frequency

The standard adult dosing for the mono-preparation is typically 480 mg of Bismuth Subcitrate equivalent per day, achieved through one of two regimens:

• Four Times Daily (Q.I.D.): 120 mg taken four times per day.
• Twice Daily (B.I.D.): 240 mg taken twice per day.

For Helicobacter pylori eradication, the bismuth component is often administered as part of a multi-drug regimen, typically involving three capsules of a combination product taken four times daily.

---

Administration Timing and Restrictions

Specific timing and constraints are followed to ensure proper application:

• Timing: Doses for the mono-preparation are generally taken 30 minutes before meals and at bedtime.
• Restrictions: Do not consume milk, dairy products, or antacids within a 2-hour period of taking Вис-Нол. Capsules/tablets must be swallowed whole with water.

---

Course Duration and Population-Specific Use

The treatment course for ulcers or gastritis is typically 4 weeks, and for H. pylori regimens, it is often 10 days. A 2-month bismuth-free interval is generally required before starting a new course. Use is avoided in patients with severe renal impairment, and safety has not been established for pediatric patients.

Research documentation / Overview of investigations

Documentation of Investigated Activity

The research documentation explored the drug's activity by examining specific receptor pathways. A study evaluated whether this investigation was associated with changes in the perception of chronic pain.

---

Efficacy and Endpoint Studies

• Investigation of Long-Term Endpoints Studies have explored whether this combination is associated with specific measured long-term endpoints in study participants. The results of a large-scale randomized controlled trial (RCT) were assessed. Researchers have investigated whether starting the therapy earlier was related to different observed outcomes.

• Analysis of Symptom Scores A study evaluated whether the treatment was related to changes in pre-defined symptom scores over a defined period. Findings from this investigation were documented in a 2022 journal publication.

• Comparison with Other Treatments Studies have compared the results associated with this treatment to those of other therapies. Direct head-to-head comparisons focusing on primary endpoints are documented in limited sources.

---

Tolerability Data Documentation

Tolerability data was collected from adults with the condition, and specific findings were documented in pre-clinical and Phase III trials. Researchers recorded the range and frequency of observed adverse events.

---

Investigating Different Participant Groups

Studies have included participants with mild cases to examine results across different participant severities. The body of research has also explored the treatment's use in different demographic groups to document any variations in observed effects.

Common questions about Вис-Нол (FAQ)

---

Q: Is it safe to take this medicine while I'm pregnant?

Official product information states that use of Bismuth Subcitrate is generally not recommended or may be contraindicated during pregnancy. Safety and risks to the fetus have not been fully established. This restriction is often strictly mandated when the drug is used as part of certain multi-drug regimens for H. pylori eradication.

---

Q: How does this drug actually help to heal my stomach ulcer?

Official information indicates that the drug aids ulcer management through multiple mechanisms. It forms a selective protective layer over the ulcer site, helping shield the tissue from corrosive stomach acid and the digestive enzyme pepsin. It is also noted for its antimicrobial activity against H. pylori and is associated with enhancing the local production of protective mucus within the stomach lining.

---

Q: What are the signs of Bismuth overdose or toxicity?

Prolonged use of Bismuth Subcitrate is associated with a risk of systemic Bismuth accumulation, which can lead to a serious, rare form of toxicity known as Neurotoxicity (Bismuth Encephalopathy). Symptoms of this complication may include confusion, slurred speech, difficulty with coordination or walking (ataxia), or muscle twitching (myoclonus). Official labeling indicates that if these signs occur, professional medical help is necessary.

---

Q: Are there any known side effects that are considered very rare?

According to the official product information, very rare side effects can be classified as Immune System Disorders, including hypersensitivity reactions such as a rash or itching. Extremely rare, serious cases of anaphylactic reaction (a severe allergic response) have also been documented. If a serious or acute reaction is suspected, official instructions indicate discontinuing the medicine and seeking immediate emergency medical help.

---

Q: If I miss a dose, what should I do?

Official dosage instructions state that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official dosage instructions advise against doubling the dose to compensate for a missed one.

---

Q: Can I drink alcohol while taking Bismuth Subcitrate?

Regulatory labeling for Bismuth products often includes warnings or restrictions against the use of alcohol during treatment and for a specified time period afterward. This caution is due to the potential for an interaction that may cause unpleasant side effects such as abdominal cramps, flushing, nausea, and vomiting.

---

Q: Does this medicine interact with birth control pills?

Official information states that the use of Bismuth Subcitrate, particularly as part of certain multi-drug regimens, may be associated with a reduced efficacy of oral contraceptives (birth control pills). This means that protection against pregnancy may be lowered. Official labeling suggests consulting a healthcare provider about the need for an additional or different form of contraception during treatment.

---

Q: How should I dispose of unused or expired medicine?

Unused or expired Bismuth Subcitrate capsules should not be thrown into household trash or flushed down the toilet. Disposal must be carried out in accordance with local pharmaceutical waste requirements to preserve the environment. Information regarding local take-back programs or specific instructions is typically available from a pharmacist or local government authority.

Official Storage and Disposal Instructions

The storage and handling of Вис-Нол (Bismuth Subcitrate) capsules must comply strictly with regulatory labeling to preserve product quality and safety.

Storage Requirement	Official Condition
Temperature	Store below 25,mathrmC. Do not freeze.
Protection	Keep in the original package. Protect from light and moisture.
Safety	Keep out of the sight and reach of children.

Storage conditions, including maintaining the required temperature and protection from environmental factors, must be upheld throughout the product's labeled shelf-life. Expired or unused capsules must not be thrown into household waste or wastewater. Disposal must be carried out in accordance with local pharmaceutical waste requirements.